Eli Lilly | LLY - بدهی های جاری





بدهی های جاری تغییر دادن تاریخ
AbbVie USD 43.29B 3.9B 2025-12
Abbott USD 16.5B 1.91B 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Baxter International USD 2.97B 805M 2025-12
Biogen USD 3.35B 59.4M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Coherus Biosciences USD 140.39M 231.91M 2025-12
Drreddys Laboratories INR 1.76B 62.5M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
J&J USD 54.13B 3.26B 2025-12
Medtronic USD 9.5B 440M 2025-12
Merck USD 28.63B 2.59B 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Novartis USD 27.28B 4.72B 2025-12
Novo Nordisk DKK 215.66B 18.7B 2025-12
Perrigo USD 1.01B 132.4M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Phibro Animal Health USD 282.37M 12.23M 2025-12
Prestige Brands USD 139.56M 4.95M 2025-12
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 28.35B 3.76B 2025-12
Sanofi EUR 28.35B 9.32B 2025-12
United Therapeutics USD 560.6M 14.3M 2025-12
Zoetis USD 2.24B 428M 2025-12